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Introduction: The aims of this present study were firstly to assess the outcome, including functional course,
in anti-Jo1 positive patients with antisynthetase syndrome (ASS), and secondly to determine predictive parameters
of poor outcome in these patients.
Methods: The medical records of 86 consecutive anti-Jo1 patients with ASS were reviewed in 4 academic centers.
Results: 13 patients (15.1%) achieved remission of ASS, whereas 55 (63.9%) improved and 18 (20.9%) deteriorated
in their clinical status. Both steroid and cytotoxic drugs could be discontinued in only 4.7% of patients. ASS was
associated with decreased quality of life at long-term follow-up: only 69.2% of patients considered to be in
remission experienced a return to previous normal activities; and 24.7% of other patients with non-remitting ASS
still had a marked reduction of activities (as shown by the disability scale of the Health Assessment Questionnaire).
Decreased quality of life was further due to calcinosis cutis (8.1%) and adverse effects of steroid therapy (36%).
Factors associated with ASS deterioration were older age, pulmonary and esophageal involvement, calcinosis cutis
and cancer. Higher anti-Jo1 levels were further associated with disease severity in ASS patients.
Conclusions: The present study shows high morbidity related to ASS. Furthermore, we suggest that patients with
predictive factors of ASS deterioration may require more aggressive therapy. Our findings also suggest that in
anti-Jo1 patients with severe esophageal manifestations, combined high dose steroids and intravenous
immunoglobulins might be proposed as the first line therapy. Finally, as cancer occurred in 14% of anti-Jo1
patients, our findings underscore that the search for cancer should be performed in these patients.Introduction
Antisynthetase syndrome (ASS) is characterized by
polymyositis/dermatomyositis (PM/DM) associated with
antisynthetase antibodies, fever, arthritis, Raynaud’s
phenomenon, mechanic’s hands and interstitial lung disease
(ILD) [1-3]. The anti-Jo1 antibody is the most common of
the antisynthetase antibodies (60% to 80%) [1-4].
ASS is still considered to be associated with high morbid-
ity rates, principally related to muscle weakness and lung
complications [4-7]. Nevertheless, to date, only a few series
have analyzed the outcome and prognostic factors in anti-
Jo1 patients with ASS. The aims of the current study were
to (1) assess outcomes, including functional course, in 86* Correspondence: isabelle.marie@chu-rouen.fr
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reproduction in any medium, provided the oranti-Jo1 patients with ASS; and (2) determine predictive
parameters of poor outcomes in these patients.
Methods
Our retrospective study began with a search of the par-
ticipating institutional centers’ medical record indexes,
which provided us access to the diagnoses of the centers’
patients. The first electronic search involved use of the
PM/DM codes to identify patients with a diagnosis of
PM/DM who were seen as either inpatients or outpa-
tients between 1996 and 2010 at four academic centers
(Lille, Paris, Rouen and Tours). The diagnosis of PM/DM
was based on Bohan and Peter criteria [8,9], and only pa-
tients with definite or probable disease were included. Dur-
ing the study period, 346 consecutive patients were seen for
evaluation of PM/DM. All patients had been tested for
anti-Jo1 antibody using immunodiffusion with subsequent
confirmation by enzyme-linked immunosorbent assay.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Jo1-positive patients with ASS. Eighty-six anti-Jo1 pa-
tients with ASS were identified. None of these patients
had other connective tissue disorders or myopathy. The
data from all patients were anonymously reported. This
retrospective study was approved by the institutional ethics
committee of CPP de Haute-Normandie with a waiver for
informed consent.
Initial evaluation of patients
At the time of diagnosis, muscle weakness, involving both
upper and lower limbs and neck extensors and flexors,
was assessed by manual muscle strength testing (MMT)
using the UK Medical Research Council Scale (0 to 5), with
a theoretical maximum score of 85 points (that is, normal
muscle power).
All patients had an initial evaluation for organ involve-




3. Joint impairment: arthralgia, arthritis (painful and/or
swollen joints) and deforming arthropathy
characterized by subluxation of interphalangeal
joints of the thumbs and periarticular hydroxyapatite
calcifications.
4. Esophageal dysfunction: The diagnosis of
PM/DM-related esophageal involvement was based
on the following:
4a. The presence of clinical manifestations, that is,
dysphagia, gastroesophageal reflux into the
pharynx and/or the mouth, coughing while
eating, and aphagia for solids and liquids.
4b. Findings of esophageal manometry: Esophageal
motor impairment related to PM/DM was
diagnosed by the presence of at least one of the
following findings: low pressure in the upper
esophageal sphincter, decreased or absent
peristalsis in the upper third of the esophageal
body and decreased peristalsis within the lower
two-thirds of the esophageal body.
4c. Gastroscopy, which was performed to exclude
esophageal mucosal involvement that might be
responsible for dysphagia that proved normal.
5. Respiratory muscle involvement resulting from
ventilatory insufficiency related to striated muscle
weakness, when patients had ventilatory failure with
decreased vital capacity: Ventilatory insufficiency
due to respiratory striated muscle weakness was
dichotomized as previously described [10]. Severe
hypoventilation was determined by hypercapnic
respiratory failure requiring mechanical ventilation,
and moderate hypoventilation was characterized bya restrictive pattern on pulmonary function tests
(PFTs) (decreased lung volumes with vital capacity
less than 80%).
6. Aspiration pneumonia.
7. Pulmonary arterial hypertension diagnosed on the
basis of echocardiography.
In addition, patients were examined for underlying
malignancy.
ILD involvement was systematically investigated initially
by PFTs and high-resolution computed tomography (HRCT)
scans of the lungs. The diagnosis of ILD was made if pa-
tients had (1) PFT abnormalities manifested by restrictive
changes (vital capacity less than 80%) and diffusing capacity
of carbon monoxide less than 70% of the predicted value
[11] and (2) radiographic abnormalities consistent with ILD
on HRCT scans of the lungs [3,12]. Because HRCT patterns
have been correlated with pulmonary histological findings,
patients with ILD were divided into three groups based
on HRCT predominant patterns indicative of crypto-
genic organizing pneumonia (COP) characterized by
consolidation and linear opacities, nonspecific interstitial
pneumonia (NSIP) characterized by ground-glass opacities
and irregular linear opacities, and usual interstitial pneu-
monia (UIP) characterized by honeycombing and traction
bronchiectases [3,12].
Patient outcomes
Patients had a minimal follow-up of 18 months, although
patients who died before the 18-month follow-up were
also included. The functional course of all patients was
assessed for muscle functional disability according to the
disability scale of the Health Assessment Questionnaire
(HAQ), which is divided into eight variables: dressing and
grooming, arising, eating, walking, hygiene, reach, grip
and activity [13].
The outcome of myositis was defined as (1) remission,
characterized by stable increase or normalization of muscle
strength (determined on the basis of MMT), skin changes
and serum muscle enzyme levels (creatine kinase, CK), all
persisting after therapy discontinuation; (2) improvement,
with therapy, in muscle signs (on the basis of MMT) and
skin changes and decreased CK levels; and (3) deterioration,
despite therapy, when muscle signs (on the basis of MMT)
and skin changes worsened and CK levels increased
[10]. ASS was defined as (1) monocyclic when patients
remained free of all clinical and biochemical signs of
disease activity at 24-month follow-up after ASS diag-
nosis and (2) chronic continuous when patients had a
chronic, progressive course of ASS and continuation of
medication beyond the 24-month follow-up after ASS
diagnosis [10]. Recurrence of myositis was diagnosed
on the basis of clinical relapse. Recurrence was divided
into two types: (1) short-term, occurring during tapering
Table 1 General characteristics of anti-Jo1 patients with
antisynthetase syndrome
Characteristics Data (N = 86 patients)
Median age, years (range) 54 (15 to 83)
Men/women (n) 32/54
Clinical manifestations, n (%)
Raynaud’s phenomenon 42 (11%)
Mechanic’s hands 26 (30.2%)
Arthralgia/arthritis 59 (68.6%)
Esophageal involvement 21 (24.4%)
Pulmonary involvement
Interstitial lung disease 55 (64%)
Ventilatory insufficiency 13 (15.1%)
Aspiration pneumonia 17 (19.8%)
Calcinosis cutis 7 (8.1%)
Malignancy 12 (13.9%)
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termination [10].
In addition, the HAQ score [13] was used to evaluate
functional disability of ASS patients at the last follow-up.
Particular attention was further paid to the development of
the following steroid-related complications: muscle weak-
ness, osteoporotic vertebral fracture and avascular necrosis.
These latter outcomes were evaluated on the basis of the
clinical records available.
Both survival and current status were based on hospital re-
cords (that is, data obtained during routine follow-up visits).
The causes of death were also derived from hospital and
physician records.
Measurement of prognostic factors
Prognostic factors were determined at the time of ASS
diagnosis. We assessed factors associated with poor
prognosis in ASS patients. Patients were divided into
two groups: patients whose condition deteriorated due
to ASS and those whose condition did not. For group
comparisons involving binary data, we used either the
χ2 test or Fisher’s exact test, depending on the expected
cell count (more or less than 5, respectively). Compari-
sons involving continuous data were performed using
the Mann–Whitney U test. The results were regarded
as significant when the P-value was less than 0.05.
Results
General background
The 86 anti-Jo1 patients comprised 32 men and 54 women
with a median age of 54 years (range: 17 to 79 years) at
the time of ASS diagnosis. Fifty-one patients had PM, and
thirty-five had DM. At the time of initial diagnosis of ASS,
74 patients presented with myalgia (86%) and 66 exhibited
muscle weakness (76.7%). The median score for muscle
power on the MMT was 66 (range: 48 to 83). The median
HAQ score for the cohort at the time of ASS diagnosis
was 0.9. HAQ-specific frequency scores in patients were
as follows: 0 < HAQ ≤ 0.5 (n = 29), 0.5 < HAQ ≤ 1 (n = 27),
1 < HAQ ≤ 1.5 (n = 12), 1.5 < HAQ ≤ 2 (n = 9), 2 < HAQ ≤
2.5 (n = 6) and 2.5 <HAQ ≤ 2.75 (n = 3).
The general clinical characteristics of anti-Jo1 patients
are shown in Table 1. ASS patients exhibited Raynaud’s
phenomenon (n = 42); mechanic’s hands (n = 26); joint
impairment (n = 59), including deforming arthropathy of
the hands (n = 3); esophageal dysfunction (n = 21) (Table 2);
and calcinosis cutis (n = 7). They also exhibited the follow-
ing pulmonary complications: (1) ILD (n = 55) (Table 2),
two of whom developed pulmonary arterial hypertension
related to ILD; (2) ventilatory insufficiency related to
striated muscle weakness (n = 13), 12 of whom had
moderate hypoventilation and 1 of whom exhibited severe
hypoventilation requiring mechanical ventilation; and (3)
aspiration pneumonia (n = 17) related to esophageal motorimpairment (n = 12) and ventilatory insufficiency due to
respiratory striated muscle weakness (n = 5).
Twelve patients (seven with DM and five with PM) had
cancer of the colon (n = 3), breast (n = 3), ovaries (n = 2),
uterus (n = 1), lung (n = 2) or pancreas (n = 1). The median
age of these patients at the time of cancer diagnosis was
61.5 years (range: 49 to 75 years). Cancer onset in these
patients preceded myositis within three years before ASS
diagnosis (n = 3), was concurrently identified in association
with ASS (n = 7) or (3) developed within two years after
ASS diagnosis (n = 2).
Therapy
All 86 patients were given high-dose steroid therapy initially
(1 mg/kg/day). Steroid therapy was started within three
months after onset of ASS symptoms in 82.6% of the cases
and within one year in 97.7%. Twenty-two patients (25.6%)
received steroids as monotherapy. Other anti-Jo1 patients
with steroid-refractory ASS were further treated with
second-line immunosuppressive agents (74.4% of cases).
Thirty patients were treated with methotrexate (MTX),
which resulted in improvement of ASS in 83.3% of cases.
Twenty-five patients were treated with azathioprine (AZA),
which resulted in improvement of ASS in 72% of cases.
Thirty-nine patients were given intravenous immunoglobu-
lins (IVIGs) (1 g/kg for two days/month; median duration:
six months), which led to clinical improvement in 69.2%
of cases. Twenty patients with esophageal involvement
received IVIG therapy (1 g/kg/day for two days/month).
The median IVIG therapy duration was six months (range:
four to nine months). Because oral feeding was impossible
in the three patients with aphagia for solids and liquids
(Table 2), these patients also required percutaneous
endoscopic gastrostomy (n = 1) or gastric intubation
Table 2 Esophageal complications and interstitial lung disease characteristics of anti-Jo1-positive antisynthetase
syndrome patientsa
Complications and characteristics Percentage (n)
Esophageal complications (N = 21)
Time of onset
Concomitant with PM/DM 19% (n = 4)
1 to 3 months after PM/DM diagnosis 28.6% (n = 6)
More than 3 months after PM/DM diagnosis 52.4% (n = 11)
Presenting symptoms
Odynophagia 4.8% (n = 1)
Dysphagia 81% (n = 17)
GER into pharynx and/or mouth 33.3% (n = 7)
Coughing while eating 61.9% (n = 13)
Aphagia for solids and liquids 14.3% (n = 3)
Esophageal manometry
Low pressure in upper esophageal sphincter 85.7% (n = 18)
Decreased peristalsis in upper third of esophageal body 85.7% (n = 18)
Absent peristalsis in upper third of esophageal body 14.3% (n = 3)
Decreased peristalsis in lower two-thirds of esophageal body 9.5% (n = 2)
Interstitial lung disease (N = 55)
Time of onset
Before PM/DM 10.9% (n = 6)
Concomitant with PM/DM 70.9% (n = 39)






COP 12.7% (n = 7)
NSIP 63.7% (n = 35)
UIP 23.6% (n = 13)
aCOP: cryptogenic organizing pneumonia; DLCO: diffusing capacity of carbon monoxide; FVC: forced vital capacity; GER: gastroesophageal reflux; HRCT:
high-resolution computed tomography; ILD: interstitial lung disease; NSIP: nonspecific interstitial pneumonia; PFT: pulmonary function test; PM/DM:
polymyositis/dermatomyositis; UIP: usual interstitial pneumonia; VC vital capacity.
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reduction of esophageal manifestations. In these patients,
a significant improvement in esophageal manifestations
occurred within two weeks after the first IVIG regimen,
and complete disappearance of esophageal impairment
was observed within fifteen days after the second IVIG
regimen. This efficacy resulted in return to normal oral
feeding and ablation of oral feeding tubes in all cases.
Seven patients with MTX/AZA-refractory ASS were
given mycophenolate mofetil (MMF), which resulted in
resolution (n = 1) or improvement (n = 3) of clinical signs
(57.1% of cases). Nineteen patients were given cyclophos-
phamide (six cycles intravenously) for ASS-related ILD,
leading to improvement and/or stabilization of lung statusin 89.4% of cases. One patient with refractory myositis and
ILD was successfully treated with rituximab as follows: 1 g
at days 0 and 14 and 1 g every 6 months for 18 months.
Outcomes
The median follow-up duration of patients was 45 months
(range: 1 to 228 months). The outcomes of these patients
are summarized in Table 3.
Thirteen patients (15.1%) had clinical remission of ASS,
and only one of these patients had monocyclic PM/DM.
At the last follow-up, only four of these thirteen patients
were receiving no therapy and the other nine patients were
being treated with low-dose prednisone alone (n = 4), MTX
(n = 3) or AZA (n = 2).
Table 3 Outcomes of anti-Jo1 patients with
antisynthetase syndromea






Chronic continuous 56 (65.1%)
Recurrences
During tapering of high-dose steroids 5 (5.8%)
During tapering of low-dose steroids 69 (80.2%)
Off treatment 1 (1.2%)
Mortality 10 (11.6%)
aASS: antisynthetase syndrome.
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ASS. Forty-four of these patients had chronic continuous
ASS. At the last follow-up, the median daily dose of
prednisone was 10 mg in these patients. These patients
concurrently received MTX (n = 20), AZA (n = 16), MMF
(n = 5) and IVIG (n = 1); prednisone therapy could be
disrupted for the other two patients, who still received
cytotoxic drugs (MTX (n = 1) and MMF (n = 1)).
Eighteen patients (20.9%) had deterioration of ASS, and
twelve had chronic continuous ASS. At the last follow-up,
the median daily dose of prednisone was 17 mg in these
patients. They also concurrently received AZA (n = 7),
MTX (n = 4), MMF (n = 2) and IVIG (n = 3).
ASS recurred in 75 patients (87.2%). Short-term recur-
rence was encountered in 74 patients; of these patients,
69 received low-dose steroids (<20 mg/day). Long-term
clinical recurrence of ASS occurred in one patient seven
months after therapy termination.
Ten anti-Jo1 patients died, with nine ASS-specific deaths
due to cancer (n = 5) or to pulmonary complications due to
respiratory insufficiency related to ILD (n = 1) or aspir-
ation pneumonia (n = 3). The longest time until death
was 163 months after onset of ASS (median: 34 months
(range: 0.1 to 163 months)).
Long-term functional outcomes
The long-term functional outcomes of the patients who
achieved ASS remission were characterized by complete
disappearance of clinical manifestations with a return
to previous normal activities in nine patients (69.2%),
persistent muscle effort fatigue with moderate decreased
activities (HAQ score < 0.75) in four patients and death due
to disorders other than ASS complications in one patient.
The long-term functional outcomes of the 73 remaining
patients were persistent muscle effort fatigue with moder-
ate decreased activities (HAQ score < 0.75) in 55 patients,marked decrease of muscle weakness with severe reduction
of activities (0.75 <HAQ score < 1.5) in 15 patients and
three patients who required a wheelchair (HAQ> 1.5).
The seven patients with calcinosis cutis developed
the disabling complications of pain (n = 5), mechanical
disturbances (n = 4), cosmetic disfigurement (n = 3) and
ulceration with infection (n = 3). Calcinosis cutis was both
extensive and diffuse in one of these patients. Patients
also exhibited the steroid-related musculoskeletal com-
plications of muscle weakness (n = 23) and osteoporotic
vertebral fracture (n = 8).
Factors associated with antisynthetase syndrome
deterioration
We compared the characteristics of patients with or with-
out ASS deterioration (Table 4). The median duration of
patient follow-up did not differ between these two groups
of patients (37 vs. 35 months; P = 0.673).
Patients who experienced ASS deterioration were
older (60.5 years vs. 53 years; P = 0.002). We found no
statistically significant difference between anti-Jo1 patients
with or without ASS deterioration regarding sex (P = 0.420),
PM/DM subset (P = 0.424), duration of clinical mani-
festations before therapy initiation (P = 0.884), myalgia
(P = 1), Raynaud’s phenomenon (P = 1), mechanic’s hands
(P = 0.767), joint involvement (P = 0.406) or ILD (P = 0.582).
Patients with ASS deterioration more commonly
exhibited muscle weakness (P = 0.05) with a lower median
score of muscle power on MMTs at initial diagnosis of
ASS (62 vs. 71; P = 0.06), calcinosis cutis (P = 0.004),
esophageal impairment (P = 0.03), ventilatory insufficiency
related to striated muscle weakness (P = 0.02) and as-
piration pneumonia (P = 0.04). We further found that
patients with ASS deterioration, compared with those
without it, presented lower median values of forced vital
capacity (69.5% vs. 75.5%; P = 0.001) and vital capacity
(68.5% vs. 75%; P = 0.001) at the time of ASS diagnosis.
The UIP predominant pattern on HRCT scans was more
frequent in the group of ILD patients with ASS deterioration
(44.4% vs. 7.4%; P =0.0005). In addition, cancer was more
frequent in the group of patients with ASS deterioration
(38.9% vs. 7.4%; P = 0.002).
Additionally, the median anti-Jo1 antibody titer was
higher in patients who developed ASS deterioration
than in those who did not at the time of initial ASS
diagnosis (98 vs. 69 U/ml; P = 0.033) and last follow-up
(135 vs. 47 U/ml; P = 0.018) (Table 5).
ASS deterioration was not associated with any of the treat-
ments: MTX (P= 0.569), AZA (P= 0.783), IVIG (P = 0.06),
MMF (P = 0.633) and cyclophosphamide (P = 0.106). At
the last follow-up, the median daily dose of prednisone was
higher in patients with ASS deterioration (17 mg vs. 8 mg;
P = 0.03). ASS deterioration tended to be more frequent
in AZA-treated patients than in the MTX-treated group,
Table 4 Clinical parameters associated with antisynthetase syndrome deteriorationa
Characteristics ASS remission/improvement ASS deterioration P
(n = 68) (n = 18)
General characteristics
Median age, years (range) 60.5 (17 to 86) 53 (19 to 83) 0.002
Male/female ratio 39.7%/60.3% 27.8%/72.2% 0.420
PM/DM subset 61.8% PM/38.2% DM 50% PM/50% DM 0.424
Median duration of ASS symptoms before diagnosis, months (range) 3 (1 to 9) 4 (1 to 13) 0.680
Clinical characteristics
Myalgia 82.4% 88.9% 1
Muscle weakness 72% 94.4% 0.05
Fever 16.2% 27.8% 0.309
Raynaud’s phenomenon 48.5% 50% 1
Mechanic’s hands 29.4% 33.3% 0.777
Joint manifestations 66.2% 77.8% 0.406
Esophageal involvement 19.1% 44.4% 0.03
Interstitial lung disease 61.8% 72.2% 0.582
Ventilatory insufficiency 10.3% 33.3% 0.02
Pyogenic pneumonia 14.7% 38.9% 0.04
Calcinosis cutis 2.9% 27.8% 0.004
Malignancy 7.4% 38.9% 0.002
aASS: antisynthetase syndrome; PM/DM: polymyositis/dermatomyositis. P values were calculated using a χ2 test or Fisher’s exact test.
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The mortality rate was higher in patients who achieved
ASS deterioration than among patients who did not
(38.9% vs. 7.4%; P = 6 × 10−6).
Discussion
Previously, investigators have evaluated PM/DM patient
outcomes. They have reported variable rates of PM/DM
remission ranging from 25% to 70% [10,14-21]. To date,Table 5 Biochemical parameters associated with antisyntheta
Biochemical parameters ASS remission/improv
(n = 68)
Overall
ESR (mm/h) 20 (range: 2 to 10
C-reactive protein (mg/L) 6 (range: 1 to 104
Hemoglobin (g/dl) 13.1 (range: 9.8 to
Total leukocyte count (giga/L) 6.9 (range: 2.5 to 20
Alanine aminotransferase (IU/L) 57 (range: 11 to 36
Aspartate aminotransferase (IU/L) 58 (range: 23 to 78
Creatine kinase (IU/L) 492 (range: 24 to 20
Anti-Jo1 antibody titer (U/ml)
At initial diagnosis of ASS 69
At last follow-up of ASS 47
aASS: antisynthetase syndrome; ESR: erythrocyte sedimentation rate. Data are media
exact test.only a few studies have assessed the outcomes of anti-Jo1
patients with ASS [6,7,22]. In a previous study of 12
anti-Jo1 ASS patients, 41.7% achieved a complete clinical
response. The remaining patients exhibited improvement
of ASS: Discontinuation of therapy was possible in one
patient (8.3%), and long-term therapy was required in
the other patients [7]. To the best of our knowledge, our
present study represents the largest series of anti-Jo1
patients with ASS. We have found that the prognosis ofse syndrome deteriorationa
ement ASS deterioration P
(n = 18)
8) 32 (range: 8 to 86) 0.09
) 13 (range: 3 to 212) 0.172
16) 12.9 (range: 10.2 to 15) 1
.7) 8.3 (range: 3.8 to 25.7) 0.443
8) 45 (range: 15 to 188) 0.763
7) 70 (range: 12 to 376) 0.537
,000) 352 (range: 39 to 10,601) 0.861
98 0.033
135 0.018
ns (ranges) unless otherwise specified. P values were calculated using Fisher’s
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without the anti-Jo1 antibody. Only 15.1% of patients in
our study achieved ASS remission, whereas clinical status
improved in 63.9% and worsened in 20.9%. Our study com-
prised 86 consecutive patients without prior selection based
on clinical presentation, which tends to be representative of
anti-Jo1 patients. Our findings are in accord with the data
reported by Love et al. [6], who found that only 4% of anti-
Jo1 patients were relapse-free at the end of their seven-year
study period. In our experience, most of the anti-Jo1
patients had a chronic continuous ASS course. Both
steroids and cytotoxic drugs could be discontinued in
only 4.7% of patients who remained stable after therapy
disruption at the last follow-up. Altogether, our data
underscore the fact that the presence of anti-Jo1 antibody
predicts the prolonged use (longer than three years) of
steroids and cytotoxic drugs in ASS patients.
Previous series have included relapse rates of 23% to
60% in PM/DM [10,13,17,23]. In 12 reported anti-Jo1
patients, relapses were frequent in ASS, occurring after
steroid therapy withdrawal (91.7%) or during tapering of
steroid therapy (41.7%) [7]. Our study interestingly dem-
onstrates that short-term recurrence (occurring during
therapy tapering) is frequent in anti-Jo1 patients, being
encountered in up to 86% of cases. Among patients who
received low-dose steroid therapy (less than 20 mg/day),
recurrences occurred in 93.2% of the cases. Long-term
recurrence of ASS (after therapy withdrawal) was uncom-
mon (1.2% of patients overall).
PM/DM still has a great impact on patients’ quality of life
[10,13,14,19]. In a previously reported series of 87 PM/DM
patients, the distribution of HAQ scores revealed that only
17.5% had no disability and 12.5% were severely disabled.
The remaining patients (70%) were mildly to moderately
disabled [24]. To the best of our knowledge, our present
study is the first to evaluate functional disability in anti-Jo1
patients with ASS. In this instance, ASS was strongly
associated with decreased functional status in patients.
Only 69% of our patients considered to be in remission
experienced a return to normal previous activities, whereas
the other patients in remission still complained of de-
creased quality of life (0 < HAQ< 0.75), despite our ability
to control active muscle and/or organ disease in these
patients. We have further shown that functional outcomes
of the nonremitting anti-Jo1 patients with ASS were poor, as
shown by the marked reduction of activities (HAQ> 0.75)
in 25% of them. Decreased quality of life also occurred due
to steroid-related myopathy and/or vertebral compression
fracture, which occurred in 36% of our patients.
In two previous series, the 10-year survival rate was
70% to 80% for anti-Jo1 patients [6,25]. In our cohort,
we found that the survival rates were 95.3%, 88.9% and
71.4% at one, five and ten years, respectively. The overall
mortality rate was 11.6% in our patients, which is higherthan that in the general population of the same mean
age, in which the five-year mortality rate is about 1% to
2%. Our study further underscores the fact that anti-Jo1
patients with ASS have a 10.5% risk of death due to a
cause related to ASS, with death in these patients being
due mainly to cancer and pulmonary complications.
High-dose oral prednisone is the mainstay of therapy
for ASS patients [23]. In patients who fail to respond to
prednisone alone (that is, patients with deterioration of
ASS clinical manifestations and increased CK levels after
at least four to eight weeks), the first-line therapy comprises
MTX and AZA [23]. Previous authors have observed
that ASS patients exhibited a better response to MTX
than to AZA [22,26]. Our findings are in accord with
these data, as we observed that MTX treatment tended
to result more frequently in ASS improvement than
AZA therapy in anti-Jo1 patients with ASS. Moreover,
MTX has the advantage of being faster-acting than AZA,
allowing improvement of muscle strength and CK levels
six to eight weeks after therapy initiation [23]. In our
experience, the proportion of ILD patients treated with
MTX and AZA did not differ. Nevertheless, MTX ther-
apy necessitates close monitoring in patients with ILD.
Because of the risk of MTX-associated lung injury, such
therapy is not recommended in the subgroup of patients
with severe ILD (on the basis of PFTs and HRCT scans).
IVIG therapy should be considered in the following groups
of patients. One is patients who fail to respond to a
combination of prednisone, MTX or AZA treatment.
IVIGs have been shown to be a useful therapy in refrac-
tory PM/DM, with reported improvement rates ranging
from 67% to 92% [23]. In this instance, IVIGs resulted
in improvement of ASS in 70% of patients. We have also
observed, interestingly, that patients who exhibited ASS
resolution or improvement, compared with those who
did not, more often tended to be those treated with
IVIGs, although not significantly so (P = 0.06). A second
patient group for whom IVIG therapy should be considered
comprises those for whom cytotoxic drugs are contraindi-
cated. Another group comprises those patients who have
esophageal involvement [23]. In a retrospective series, 73
patients with steroid-refractory esophageal involvement
related to PM/DM received IVIG therapy. Sixty of the
IVIG-treated patients in that series had rapid resolution
of clinical manifestations related to esophageal dysfunction
(82.2%) [27]. In our current study, we found that IVIG
therapy led to improvement of esophageal involvement in
90% of patients. We further suggest that, in patients with
severe esophageal manifestations, combined high-dose
steroids and IVIGs might be proposed as the first-line
therapy. To date, in patients who fail to respond to a
combination of prednisone, MTX/AZA and IVIG, the
first-line treatment option has included rituximab. On
the basis of data obtained from case reports and open
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with PM/DM refractory to other therapies [23]. In a recent
randomized series, 200 patients (76 with PM, 76 with DM
and 48 with juvenile DM) received rituximab and cortico-
steroids and immunosuppressive therapy were allowed at
study entry [28]. The authors of that study found that 83%
of the rituximab-treated patients had improvement of
clinical manifestations at the 44-week follow-up [28]. In
our experience, one patient with refractory ASS and ILD
was successfully treated with rituximab.
Current therapy for ILD in ASS is based on the use of
steroids [3,12]. Previous studies have found a better
response to steroid therapy in anti-Jo1 patients with NSIP
and COP compared with those with UIP [3,12]. In this
instance, ASS patients with UIP had a worse prognosis than
patients with NSIP and/or COP. Cyclophosphamide may
improve the clinical outcomes in these patients [3,12,23]. In
a retrospective study, cyclophosphamide (three to six cycles
intravenously) was used in 25 PM/DM patients with ILD,
which resulted in resolution (24%) or improvement (40%)
of pulmonary status [3]. The present series also suggests
that pulse cyclophosphamide is useful in ASS patients
with ILD, resulting in resolution or improvement of pul-
monary status in 89.4% of cases. We further suggest that
patients with factors predictive of ILD deterioration
(that is, UIP pattern on HRCT scans) may require com-
bined therapy with prednisone and cyclophosphamide.
Additionally, rituximab has been suggested to be effective
in PM/DM patients with refractory ILD [2,3]. In our
experience, one patient with refractory myositis and ILD
was successfully treated with rituximab as follows: 1 g at
days 0 and 14 and 1 g every 6 months for 18 months. To
date, there is anecdotal evidence that tacrolimus is effective
in ASS patients with refractory ASS and ILD [23].
From a practical point of view, knowledge of prognostic
factors regarding the ASS course is crucial. The most im-
portant predictor of mortality is age, with older PM/DM
patients having a poorer prognosis [10,15-18,24,26,29]. In
this instance, older age (60.5 vs. 53 years) was correlated
with ASS deterioration data in anti-Jo1 patients.
Esophageal involvement has been associated with higher
mortality in PM/DM patients [10,15,17,27]. Respiratory
muscle involvement also has been described to be a factor
predictive of death in PM/DM patients [12,13,15,29,30]. In
this instance, predictive factors of ASS deterioration in
anti-Jo1 patients were muscle weakness, esophageal impair-
ment, ventilatory insufficiency related to striated muscle
weakness and aspiration pneumonia. Our findings suggest
that this group of patients may require aggressive therapy
with short-term efficacy. In addition, our findings show that
calcinosis cutis may be a factor predictive of poor outcome,
resulting in disabling functional and esthetic complications.
Another main observation can be drawn from our study.
Previous authors have found an increased risk of canceramong DM patients (odds ratio (OR): 6.2, 95% confidence
interval (CI): 3.9 to 10.0) and PM patients (OR: 2.0, 95%
CI: 1.4 to 2.7). Although the risk of cancer was highest
around the time of PM/DM diagnosis, the increased risk
persisted beyond five years (OR: 1.6, 95% CI: 1.0 to 2.6)
[31]. Cancer-associated myositis in the presence of ASS
has also been reported [32-34]. In a series of 95 ASS
patients, patients with the anti-Jo1 antibody more com-
monly had cancer than those with the anti-threonyl-tRNA
synthetase (anti-PL7)/PL12 antibody [3]. In this instance,
we found that up to 13.9% of anti-Jo1 patients with ASS
developed cancer either concurrently or within three years
before or after PM/DM onset. Our findings interestingly
underscore the fact that the prevalence of cancer was
higher in our 86 anti-Jo1 patients with ASS than in
age- and sex-matched individuals in the general popu-
lation (OR: 6.75, 95% CI: 1.4319 to 64.081; P = 0.009).
We therefore suggest that anti-Jo1 patients with ASS
(especially those older than 50 years of age) require
evaluation for cancer. Interestingly, 33.3% and 50% of
our patients with cancer developed digestive (mainly colon)
and gynecologic (ovarian, uterine and breast) cancers,
respectively. Furthermore, cancer is considered to be a
factor contributing to a poor prognosis in PM/DM patients
[10,14,15,21,35,36]. In a previous study of 197 PM/DM
patients, cancer was positively associated with mortality
(hazard ratio: 2.30, 95% CI: 1.26 to 4.22; P = 0.003) [34].
Our present study shows that cancer is highly associated
with ASS deterioration in anti-Jo1 patients (P = 0.002),
and five patients died of cancer.
The last relevant finding in our study is that the level
of anti-Jo1 antibody was higher in the group of patients
who exhibited ASS deterioration at initial evaluation and
last follow-up. We suggest that high anti-Jo1 levels may be
a factor predictive of ASS deterioration. However, further
investigations are required to confirm our findings.
Conclusion
Our large study shows high morbidity related to ASS in
anti-Jo1 patients. Only 15.1% of patients achieved remission
of ASS, and both steroids and cytotoxic drugs could be
discontinued in 4.7% of cases. Furthermore, we suggest that
patients with factors predictive of ASS deterioration may
require more aggressive therapy. Our findings also suggest
that in anti-Jo1 patients with severe esophageal manifesta-
tions, combined high-dose steroids and IVIGs might be
proposed as the first-line therapy. Cancer occurred in up to
14% of our patients, so we think a search for cancer should
be performed in anti-Jo1 patients with ASS.
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